Metastasis‐enhancing protein KITENIN confers temozolomide resistance on glioblastoma with unmethylated MGMT via upregulation of cancer stem cell makers.

This article explores the role of the protein KITENIN in promoting resistance to the chemotherapy drug temozolomide (TMZ) in glioblastoma (GBM) patients with unmethylated MGMT promoter status. The study reveals that KITENIN enhances resistance to TMZ by increasing the expression of cancer stem cell markers CD44 and ALDH1A1. The researchers also investigate the use of usnic acid (UA), a KITENIN inhibitor, and find that it reduces KITENIN expression and inhibits tumor growth. The study concludes that targeting KITENIN could potentially improve treatment outcomes for GBM patients with unmethylated MGMT. [Extracted from the article]